Core Viewpoint - King活医药集团 (01110) has announced a proposed acquisition involving its wholly-owned subsidiary, King活医药 (BVI), which is expected to be paid in cash [1] Group 1: Acquisition Details - The total consideration for the acquisition includes a base purchase price of HKD 66.4368 million, comprising HKD 41.5 million for the target company's related business and production equipment (excluding vehicles) and HKD 24.9368 million for real estate properties [1] - The consideration will also include the net book value of the target company's equipment (excluding any vehicles) at completion and the net working capital at completion, which is defined as the total of accounts receivable and inventory minus accounts payable, subject to adjustments based on audited accounts prepared in accordance with Hong Kong Financial Reporting Standards [1] - A deposit of approximately HKD 3.3218 million will be paid to the proposed seller within five business days from the signing of the memorandum of understanding [1] Group 2: Strategic Implications - The target company is registered in Hong Kong and primarily engaged in the production and sale of pharmaceuticals, operating within real estate properties [1] - The board believes that if the proposed acquisition is realized, it will enable the group to expand its footprint in the Hong Kong pharmaceutical industry, acquire valuable manufacturing assets including real estate properties, and promote the group's domestic and international business development through synergies in product distribution and operational scale [1]
金活医药集团(01110)拟收购一间香港医药公司